• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The value of Innovative Medicine: The clinical and economic impact of the first gene therapy for hemophilia B

News
Article

Sponsored Content

Content provided by CSL Behring. Copyright 2023 and published by MJH Life Sciences®. No portion of this program may be reproduced or transmitted in any form, by any means, without the prior written permission of MJH Life Sciences. The views and opinions expressed in this material do not necessarily reflect the views and opinions of MJH Life Sciences, or Managed Healthcare Executive®.


Advertorial: The value of Innovative Medicine. The clinical and economic impact of the first gene therapy for hemophilia B


© 2024 MJH Life Sciences

All rights reserved.